BDR PHARMACEUTICALS INTERNATIONAL PVT.

About BDR PHARMACEUTICALS INTERNATIONAL PVT.

BDR Group of companies has grown steadily and become a house-hold name in the pharmaceutical Industry over the last 14 years, in both domestic and international arenas. We are recognised as a “niche” player in manufacturing of Pharmaceutical APIs and for our renowned new age formulations. Core strength lies in identification of newer molecules, development and commercialisation. The group is complemented majorly by its two companies - BDR Pharmaceuticals International Pvt Ltd and BDR Life sciences Pvt. Ltd, each one having stamped its own supremacy in respective fields, i.e. API and formulation manufacturing, respectively.

BDR Group focuses on development in 4 specialized therapeutic segments, viz. Oncology, Critical care, Gynecology & Neurology, which are its dream segments. BDR‘s philosophy of sustained growth and consolidation is achieved by strategic tie-ups with several globally renowned players

  • IN
  • 2015
    On CPHI since
Contact info
Meet us at

CPHI Frankfurt 2022

Messe Frankfurt, Germany
1-3 November 2022

Products from BDR PHARMACEUTICALS INTERNATIONAL PVT. (5)

  • [(2,6- dimethylphenyl) aminocarbonylmethyl]-chloride [1311-01-7]

    Product [(2,6- dimethylphenyl) aminocarbonylmethyl]-chloride [1311-01-7]

    Bdr pharmaceuticals international pvt manufactures a pharmaceutical apis, intermediates, finish formulations which includes [(2,6- dimethylphenyl) aminocarbonylmethyl]-chloride [1311-01-7]. It belongs to ranolazine intermediates products category. Contact us for more information.
  • [1-hydroxy-2-(3-pyridinyl) ethylidene]-biphosphonic acid [105462-24-6]

    Product [1-hydroxy-2-(3-pyridinyl) ethylidene]-biphosphonic acid [105462-24-6]

    Bdr pharmaceuticals international pvt manufactures a pharmaceutical apis, intermediates, finish formulations which includes [1-hydroxy-2-(3-pyridinyl) ethylidene]-biphosphonic acid [105462-24-6]. It belongs to risedronate sodium intermediates products category. Contact us for more information.
  • [1,1'-biphenyl]-2-carbonitrile-4-[(2-butyl-4-oxo-1,3-diazaspiro [4.4]-non- 1-en-3-yl)- methyl]

    Product [1,1'-biphenyl]-2-carbonitrile-4-[(2-butyl-4-oxo-1,3-diazaspiro [4.4]-non- 1-en-3-yl)- methyl]

    Bdr pharmaceuticals international pvt manufactures a pharmaceutical apis, intermediates, finish formulations which includes [1,1'-biphenyl]-2-carbonitrile-4-[(2-butyl-4-oxo-1,3-diazaspiro [4.4]-non- 1-en-3-yl)- methyl]. It belongs to irbesartan intermediates products category. Contact us for more information...
  • [138401-24-8]

    Product [138401-24-8]

    Bdr pharmaceuticals international pvt manufactures a pharmaceutical apis, intermediates, finish formulations which includes [138401-24-8]. It belongs to irbesartan intermediates products category. Contact us for more information.
  • 1- (2-methoxyphenoxy) -2,3-epoxypropane. [2210-74-4]

    Product 1- (2-methoxyphenoxy) -2,3-epoxypropane. [2210-74-4]

    Bdr pharmaceuticals international pvt manufactures a pharmaceutical apis, intermediates, finish formulations which includes 1- (2-methoxyphenoxy) -2,3-epoxypropane. [2210-74-4]. It belongs to ranolazine intermediates products category. Contact us for more information.

BDR PHARMACEUTICALS INTERNATIONAL PVT. Resources (1)